Home > News > Nanoparticle tech to develop oral HIV vaccine
August 8th, 2007
Nanoparticle tech to develop oral HIV vaccine
Emerging specialty pharmaceutical company Nanotherapeutics will be using its nanoparticle drug delivery technology to develop an HIV oral peptide vaccine after entering into a two year agreement with the National Cancer Institute (NCI).
The Florida-based company will use its proprietary NanoDRY drug delivery technology to develop the peptide vaccine candidate into an oral form which will have targeted delivery to the lower gastrointestinal (GI) tract.
Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of Nanostart-holding MagForce AG June 17th, 2013
Iranian Scientists Produce Dynamometer for Nanoparticles, Biocells June 15th, 2013
Monell-led research identifies scent of melanoma: New research may lead to early non-invasive detection and diagnosis June 14th, 2013
Discovery of new material state counterintuitive to laws of physics June 14th, 2013
An Innovative material for the Green Earth: Simple and inexpensive process to make a material for CO2 adsorption June 17th, 2013
Polymer-coated catalyst protects "artificial leaf" June 17th, 2013
Efficient and inexpensive: Researchers develop catalyst material for fuel cells: Platinum-nickel nano-octahedra save 90 percent platinum June 17th, 2013
AXEON Acquires Assets of Leading Reverse Osmosis Systems Manufacturer June 17th, 2013